## Abstract ## Background. The purpose of this prospective study was to evaluate whether a relationship exists between malnutrition (≥10% weight loss) and health‐related quality of life (HRQL) in patients with head and neck cancer and whether weight loss can be predicted with HRQL questionnaires.
Predictors of weight loss during radiotherapy in patients with stage I or II head and neck cancer
✍ Scribed by Alice Nourissat; Isabelle Bairati; Elodie Samson; André Fortin; Michel Gélinas; Abdenour Nabid; François Brochet; Bernard Têtu; François Meyer
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 176 KB
- Volume
- 116
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND:
The purpose of the study was to identify predictors of weight loss during radiotherapy (RT) in patients with stage I or II head and neck (HN) cancer.
METHODS:
This study was conducted as part of a phase 3 chemoprevention trial. A total of 540 patients were randomized. The patients were weighed before and after RT. Their baseline characteristics, including lifestyle habits, diet, and quality of life, were assessed as potential predictors. Predictors were identified using multiple linear regressions. The reliability of the model was assessed by bootstrap resampling. A receiver operating characteristics curve was generated to estimate the model's accuracy in predicting critical weight loss (≥5%).
RESULTS:
The mean weight loss was 2.2 kg (standard deviation, 3.4). Five factors were associated with a greater weight loss: all HN cancer sites other than the glottic larynx (P<.001), higher pre‐RT body weight (P<.001), stage II disease (P = .002), dysphagia and/or odynophagia before RT (P = .001), and a lower Karnofsky performance score (P = .028). There was no association with pre‐RT lifestyle habits, diet, or quality of life. The bootstrapping method confirmed the reliability of this predictive model. The area under the curve was 71.3% (95% confidence interval, 65.8‐76.9), which represents an acceptable ability of the model to predict critical weight loss.
CONCLUSIONS:
These results could be useful to clinicians for screening patients with early stage HN cancer treated by RT who require special nutritional attention. Cancer 2010. © 2010 American Cancer Society.
📜 SIMILAR VOLUMES
## Abstract ## Background. The purpose of this study was to determine the influence of weight loss on outcome in patients with head and neck cancer undergoing concomitant chemoradiotherapy (CCRT): treatment interruption, infections, mortality, and hospital readmission rate. ## Methods. Forty pat
## Abstract ## BACKGROUND Amifostine was developed to protect normal tissues from radiation exposure. The current study was undertaken to determine whether amifostine would allow the delivery of greater numbers of weekly paclitaxel treatments with concomitant, hyperfractionated radiotherapy in pat
## Abstract ## Background. The aims of this study were to determine the recommended dose (RD) in combination chemotherapy of S‐1 and carboplatin in recurrent and/or metastatic head and neck cancer (phase I) and to examine response rate and toxicities at RD (phase II). ## Methods. S‐1 was given o
I strated49 5. 7, 10, 11 that protracted intraarterial Chemotherapy with cytotoxic agents is particularly effective in shrinking or causing transient complete regression in cancer. Rest results have been observed in head and neck, limb, and liver cancer, as the specific vascularization of these area